⌘K
Loading ticker…
As of 2026-08-24, Arcus Biosciences, Inc. (RCUS) has a 3-month relative strength percentile of 87 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 71. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.4%, relative volume 1.06×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RCUS is in a stage 2 uptrend, week 4. Currently in a 39-day base; basing ADR 4.6% (broad 5.8%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 5.8% / 24.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
RCUS is held by 27 ETFs as of May 2026. Top owner: VTWO at 0.06% weight, $11M notional. Top 3 carry $29M.
Held by 80 ETFs · $493M across latest filings · largest weight 2.12% (IDNA).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.06% | $11M | +0.01 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.05% | $10M | — |
| VIOOVanguard S&P Small-Cap 600 ETF | 0.13% | $7M | +0.02 pp |
| VHTVanguard Health Care ETF | 0.03% | $7M | — |
| VFMO | 0.17% | $3M |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| +0.12 pp |
| CANC | 1.20% | $2M | +0.61 pp |
| VIOVVanguard S&P Small-Cap 600 Value ETF | 0.09% | $2M | +0.01 pp |
| VIOGVanguard S&P Small-Cap 600 Growth ETF | 0.16% | $2M | +0.02 pp |
| DWAS | 0.36% | $2M | +0.03 pp |
| PSCH | 1.15% | $2M | +0.11 pp |
Showing 10 of 27 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCUS Jan avg: -10.30% median: -12.54% win: 25% σ: 10.68% n: 4 2022-04-12 → 2026-07-31 | RCUS Feb avg: -2.06% median: -9.38% win: 25% σ: 19.84% n: 4 2022-04-12 → 2026-07-31 | RCUS Mar avg: -5.75% median: -0.57% win: 50% σ: 15.11% n: 4 2022-04-12 → 2026-07-31 | RCUS Apr avg: -2.94% median: -2.14% win: 40% σ: 18.11% n: 5 2022-04-12 → 2026-07-31 | RCUS May avg: -1.26% median: -0.63% win: 40% σ: 13.20% n: 5 2022-04-12 → 2026-07-31 | RCUS Jun avg: 9.30% median: 1.06% win: 60% σ: 17.71% n: 5 2022-04-12 → 2026-07-31 | RCUS Jul avg: 2.85% median: 4.93% win: 60% σ: 8.20% n: 5 2022-04-12 → 2026-07-31 | RCUS Aug avg: 3.47% median: 3.67% win: 75% σ: 10.40% n: 4 2022-04-12 → 2026-07-31 (current) | RCUS Sep avg: 3.48% median: -1.03% win: 50% σ: 19.17% n: 4 2022-04-12 → 2026-07-31 | RCUS Oct avg: 7.50% median: -1.27% win: 50% σ: 25.58% n: 4 2022-04-12 → 2026-07-31 | RCUS Nov avg: 16.79% median: 16.63% win: 75% σ: 21.47% n: 4 2022-04-12 → 2026-07-31 | RCUS Dec avg: -6.66% median: -6.13% win: 25% σ: 27.86% n: 4 2022-04-12 → 2026-07-31 |